Magle Chemoswed (MAGLE) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue rose to 85.1 MSEK from 42.3 MSEK year-over-year, with EBITDA at 18.8 MSEK (7.0 MSEK) and EBIT at 2.1 MSEK (4.2 MSEK). Profit after tax was -1.2 MSEK (2.9 MSEK).

• Strategic acquisitions (Saving Chlora, PK Chemicals, Amniotics) expanded capabilities in biopolymers, biopharma, and advanced wound care.

• New business units Magle Biopolymers and Magle Biopharma established, with early synergies and revenue contributions.

• Organic growth in DSM and CDMO segments, supported by increased project requests and clinical collaborations.

Financial highlights

• Full-year 2024 revenue was 256.1 MSEK (183.1 MSEK), EBITDA 58.9 MSEK (31.1 MSEK), EBIT 23.2 MSEK (18.0 MSEK), and profit after tax 11.9 MSEK (12.2 MSEK).

• Q1 2025 EPS was -0.07 SEK (0.27 SEK), with shareholders' equity per share at 26.8 SEK (14.9 SEK).

• Cash flow from operating activities in Q1 2025 was 4.7 MSEK, with net cash flow of 3.2 MSEK.

• Equity ratio at quarter-end was 54% (56%).

Outlook and guidance

• 2025 investments target efficiency and long-term profitability, with a consolidatory first half as new acquisitions are integrated.

• Focus remains on sustainable growth via organic expansion, acquisitions, and technological advancement.

• Capital structure optimization is underway to ensure financial flexibility for growth strategy execution.